Compass Therapeutics, Inc. (CMPX)
| Market Cap | 331.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -66.49M |
| Shares Out | 180.09M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,077,307 |
| Open | 1.905 |
| Previous Close | 1.790 |
| Day's Range | 1.795 - 2.180 |
| 52-Week Range | 1.610 - 6.880 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 14.57 (+691.85%) |
| Earnings Date | May 6, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $14.57, which is an increase of 691.85% from the latest price.
News
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on C...
Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients
Compass Therapeutics Inc. (NASDAQ:CMPX) shares are tumbling on Monday as the company announced results from its COMPANION-002 study, which evaluated its drug tovecimig in patients with advanced biliar...
Compass Therapeutics Transcript: Study update
The COMPANION-002 trial in advanced biliary tract cancer met its primary and key secondary endpoints, with tovecimig plus paclitaxel significantly improving response rate and progression-free survival versus paclitaxel alone. Crossover-adjusted analyses suggest a strong survival benefit, and the safety profile was manageable.
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi...
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was re...
Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Four clinical-stage antibody programs are advancing, with tovecimig showing strong efficacy in biliary tract cancer and poised for key survival readouts. Commercialization plans target a >$1B U.S. market, with expansion into other indications and strategic partnerships under consideration.
Compass Therapeutics Provides Corporate Update
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)...
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics Announces Key Leadership Appointments
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to...
Compass Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Multiple oncology assets are advancing, with Tevecimig showing strong efficacy in BTC and a pivotal PFS/OS readout expected in Q1 2026. PD-1, PD-L1 bispecifics demonstrate unique mechanisms and early responses in refractory patients, while commercial and prescriber readiness is ramping up for a potential 2027 launch.
Compass Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Lead bispecific antibody Tovecimig demonstrated strong efficacy in advanced biliary tract cancer, with pivotal PFS/OS data expected by end of Q1 and a BLA filing planned for the second half of the year. Pipeline programs 8371 and 10726 are advancing, with global commercialization strategies under consideration.
Compass Therapeutics to Participate in Upcoming December Investor Events
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, to...
Compass Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Multiple antibody-based oncology drugs are advancing, with a lead bispecific showing significant efficacy in biliary tract cancer and key survival data expected in late Q1 2026. Early results from other pipeline assets are promising, and commercial opportunities are substantial.
Compass Therapeutics Transcript: Stifel 2025 Healthcare Conference
COMPANION-002 trial of Tovecimig in second-line BTC shows fewer deaths than expected, suggesting a strong treatment effect, with top-line data due in late Q1 2026. Pipeline assets 8371 and CTX-10726 show promising early results, and the company is well-funded to advance multiple programs.
Compass Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Four antibody-based oncology drugs will be in the clinic by early next year, with key data readouts expected in 2026. The lead program, Tuvesimig, showed a significant response rate improvement in BTC, with PFS and OS data due in late Q1. Additional pipeline programs are advancing, with robust early efficacy and safety signals.
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), t...
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperforme...
Compass Therapeutics to Participate in Upcoming November Investor Events
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ther...
Compass Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Significant clinical progress was reported for Tavecimab in biliary tract cancer, with updated survival data and expanded studies planned. Novel bispecific antibodies H371 and 10726 showed promising early results, and strong manufacturing and financial positions support upcoming milestones.
Compass Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Multiple antibody-based oncology programs showed strong clinical and preclinical results, with Tovecimig poised for U.S. commercialization and a projected $1B+ market. New studies and regulatory filings are planned for the coming year, supported by robust funding.
Compass Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Key clinical milestones include strong efficacy signals for tovecimig in biliary tract cancer and promising early results for bispecific antibodies in other cancers. Regulatory strategy focuses on full approval with robust data, while commercial plans target a >$3B U.S. market opportunity.
Compass Therapeutics to Participate in Upcoming September Investor Events
BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ther...
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ther...